Ivermectin Substipharm (Ivermectin)

Ivermectin is an antiparasitic macrocyclic lactone used to target nematode and ectoparasite infections.

• Strongyloidiasis: eradicates intestinal larvae, interrupting the life cycle and preventing chronic infection.
• Onchocerciasis: kills microfilariae in the skin and eyes, reducing disease manifestations.
• Scabies: eliminates the Sarcoptes scabiei mite, relieving itching and skin lesions.
• Lymphatic filariasis: reduces microfilarial load, aiding in disease control and transmission interruption.

• Ivermectin binds selectively to glutamate‑gated chloride channels found in invertebrate nerve and muscle cells. This binding increases chloride ion influx, leading to hyperpolarization of the cell membrane, paralysis of the parasite, and ultimately its death. The drug has minimal affinity for mammalian chloride channels, which contributes to its safety profile when used as directed.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient feeling of light‑headedness.
• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, usually self‑limiting.
• Headache: mild to moderate intensity.
• Pruritus: itching without rash.
• Mild skin rash: localized erythema.

Serious or Rare Side Effects

• Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Neurologic toxicity (e.g., seizures, ataxia): may occur with high plasma levels.
• Hypotension: sudden drop in blood pressure.
• Anaphylaxis: acute allergic response.
• Visual disturbances: blurred vision or ocular pain.

Before prescribing Ivermectin Substipharm, clinicians should consider several safety factors.

• Pregnancy: safety not established; use only if potential benefits outweigh risks.
• Breastfeeding: unknown excretion in milk; evaluate risk versus benefit.
• Hepatic impairment: dose adjustment may be required; monitor liver function.
• Renal impairment: use with caution in severe renal disease.
• Concomitant neurotoxic drugs: avoid or monitor for additive neurotoxicity.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Ivermectin may interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma concentrations.
• Co‑administration with other neurotoxic agents (e.g., albendazole, levamisole): heightened risk of neurologic adverse events.
• Warfarin: potential enhancement of anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

• Mild CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivermectin exposure and efficacy.
• P‑gp substrates (e.g., digoxin): possible alteration of drug levels.
• Anticholinergic agents: may increase risk of constipation.